SCHEMBL3072005

SCHEMBL3072005

COC(=O)C1CC(=O)CC(C(=O)O)N1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
CYP2D6 P10635 2/20 0.41
LMNA P02545 2/20 0.41
BLM P54132 2/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 2/20 0.41
ALOX15 P16050 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
THRB P10828 1/20 0.41
PMP22 Q01453 1/20 0.41
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
BRD4 O60885 1/20 0.36
MMP2 P08253 1/20 0.36
ANPEP P15144 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3072002 0.92 KMT2A (0.43) KMT2ACYP2D6TSHRMEN1ALOX15
SCHEMBL3072000 0.92 KMT2A (0.43) KMT2ACYP2D6TSHRMEN1ALOX15
SCHEMBL24346570 0.81 KDM4E (0.40) KMT2ACYP2D6TSHRMEN1ALOX15
SCHEMBL26041476 0.81 KDM4E (0.40) KMT2ACYP2D6TSHRMEN1ALOX15
SCHEMBL24346569 0.81 KDM4E (0.40) KMT2ACYP2D6TSHRMEN1ALOX15
SCHEMBL26041506 0.81 KDM4E (0.40) KMT2ACYP2D6TSHRMEN1ALOX15
SCHEMBL9352571 0.78 CYP2D6 (0.64) KMT2ACYP2D6LMNABLMTSHR
SCHEMBL9352580 0.78 CYP2D6 (0.64) KMT2ACYP2D6LMNABLMTSHR
SCHEMBL13956843 0.78 CYP2D6 (0.64) KMT2ACYP2D6LMNABLMTSHR
SCHEMBL9352584 0.78 CYP2D6 (0.64) KMT2ACYP2D6LMNABLMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267747-A1 5-(Arylsulfonyl)-Pyrazolopiperidines ELAN PHARMACEUTICALS, INC. (US) 2010-10-21 US disclosed
US-7732609-B2 5-(arylsulfonyl)-pyrazolopiperidines ELAN PHARMACEUTICALS, INC. (US) 2010-06-08 US disclosed
EP-1957458-A2 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES Elan Pharmaceuticals Inc. (US) 2008-08-20 EP disclosed
US-20070155753-A1 5-(Arylsulfonyl)-Pyrazolopiperidines ELAN PHARMACEUTICALS, INC. 2007-07-05 US disclosed
WO-2007064914-A2 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES ELAN PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155753-A1 5-(Arylsulfonyl)-Pyrazolopiperidines PSEN1, PSEN2, C1S KMT2A 582/4885CYP2D6 362/4885LMNA 2252/4885
US-20100267747-A1 5-(Arylsulfonyl)-Pyrazolopiperidines PSEN1, PSEN2, C1S KMT2A 582/4885CYP2D6 362/4885LMNA 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.